We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NuVasive's TLX Interbody System Gets Expanded FDA Approval
Read MoreHide Full Article
NuVasive, Inc. received an expanded 510(k) clearance from the FDA for its TLX interbody system. The TLX interbody system is inserted through a conventional transforaminal lumbar interbody fusion (TLIF) approach. TLX implants can be placed easily into the disc space due to their low profile, bulleted design. TLX is designed for a minimally-invasive spine surgery approach.
TLX interbodies were available in 15 degree lordotic options and were only indicated for use with allograft before the receipt of the approval. According to the company, new clearance includes an expandable 20 degree interbody and broader indications for use, including use with allogeneic bone graft and in additional levels of the spine. The TLX system's size offers many options for varying patient size and anatomic considerations.
The TLX interbody system, combined with the Integrated Global Alignment (iGA) suite of the company’s software, has the ability to improve overall TLIF procedures.
Notably, NuVasive is currently leaving no stone unturned to cash in on the rapidly-evolving spine market. During the last reported second quarter of 2017, the company’s core U.S. spinal hardware business maintained the bullish trend with 3% growth. The upside was driven by strong adoption of ReLine posterior fixation system within the company’s iGA platform. The company also witnessed a steady uptake of its recently-launched expandable interbody cages and base TI interfixated within the ALIF procedure.
Meanwhile, the company recently closed the acquisition of Vertera Spine, a start-up company in the spine space. NuVasive also announced the commercial launch of LessRay software technology system. It particularly works to help address overexposure to radiation in hospital operating rooms (O.R.), mostly in the case of minimally invasive spine surgery (MIS).
According to a report by GlobalData, the global market for spinal fusion is expected to rise around $9 billion by 2023, at a CAGR of 3.4%. Considering the substantial potential of the market, we believe the latest development is a strategic one.
The spine market is dominated by many well-established players like Stryker Corporation (SYK - Free Report) , Zimmer Biomet Holdings, Inc. (ZBH - Free Report) and RTI Surgical , among others.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
NuVasive's TLX Interbody System Gets Expanded FDA Approval
NuVasive, Inc. received an expanded 510(k) clearance from the FDA for its TLX interbody system. The TLX interbody system is inserted through a conventional transforaminal lumbar interbody fusion (TLIF) approach. TLX implants can be placed easily into the disc space due to their low profile, bulleted design. TLX is designed for a minimally-invasive spine surgery approach.
TLX interbodies were available in 15 degree lordotic options and were only indicated for use with allograft before the receipt of the approval. According to the company, new clearance includes an expandable 20 degree interbody and broader indications for use, including use with allogeneic bone graft and in additional levels of the spine. The TLX system's size offers many options for varying patient size and anatomic considerations.
The TLX interbody system, combined with the Integrated Global Alignment (iGA) suite of the company’s software, has the ability to improve overall TLIF procedures.
Notably, NuVasive is currently leaving no stone unturned to cash in on the rapidly-evolving spine market. During the last reported second quarter of 2017, the company’s core U.S. spinal hardware business maintained the bullish trend with 3% growth. The upside was driven by strong adoption of ReLine posterior fixation system within the company’s iGA platform. The company also witnessed a steady uptake of its recently-launched expandable interbody cages and base TI interfixated within the ALIF procedure.
Meanwhile, the company recently closed the acquisition of Vertera Spine, a start-up company in the spine space. NuVasive also announced the commercial launch of LessRay software technology system. It particularly works to help address overexposure to radiation in hospital operating rooms (O.R.), mostly in the case of minimally invasive spine surgery (MIS).
According to a report by GlobalData, the global market for spinal fusion is expected to rise around $9 billion by 2023, at a CAGR of 3.4%. Considering the substantial potential of the market, we believe the latest development is a strategic one.
The spine market is dominated by many well-established players like Stryker Corporation (SYK - Free Report) , Zimmer Biomet Holdings, Inc. (ZBH - Free Report) and RTI Surgical , among others.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>